Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF).
Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. Dr. Mikhael is the Chair of the Diversity, Equity and Inclusion Council for TGen.
Dr. Mikhael is currently the principal investigator of many clinical trials in multiple myeloma. His other interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group and serves on the Executive Committee of the American Society of Hematology as Treasurer.
Dr. Mikhael leads the diversity efforts of the IMF, known as the M-Power program, seeking to empower patients and communities change the course of myeloma in at risk populations. Dr. Mikhael also spends about 20% of his time in the third world seeking ways to enhance research, collaboration and access to myeloma therapies in underprivileged countries.